Abstract

There is a growing understanding that the early phases of type 1 diabetes (T1D) are characterised by a deleterious dialogue between the pancreatic beta cells and the immune system. This, combined with the urgent need to better translate this growing knowledge into novel therapies, provided the background for the JDRF–DiabetesUK–INNODIA–nPOD symposium entitled ‘Islet cells in human T1D: from recent advances to novel therapies’, which took place in Stockholm, Sweden, in September 2022. We provide in this article an overview of the main themes addressed in the symposium, pointing to both promising conclusions and key unmet needs that remain to be addressed in order to achieve better approaches to prevent or reverse T1D.

Original languageEnglish
Article numbere230082
JournalJournal of Endocrinology
Volume259
Issue number1
DOIs
StatePublished - Oct 2023
Externally publishedYes

Keywords

  • autoimmune
  • diabetes
  • insulin secretion
  • islet
  • pancreas

Fingerprint

Dive into the research topics of 'Islet cells in human type 1 diabetes: from recent advances to novel therapies – a symposium-based roadmap for future research'. Together they form a unique fingerprint.

Cite this